Post-therapy serum prostate-specific antigen level and survival in patients with androgen-independent prostate cancer.

No abstract is available for this paper.

• Publication year

  1999

• Venue

  Journal of the National Cancer Institute

• Publication date

  1999-02-03

• Fields of study

  Medicine

• Identifiers
  DOI 10.1093/JNCI/91.3.244PMID 10037102
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Journal of the National Cancer Institute, Vol. 29, 1962: Action of bacterial polysaccharide on tumors. II. Damage of sarcoma 37 by serum of mice treated with Serratia marcescens polysaccharide, and induced tolerance.

  2009cited by this paper
• The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group.

  2002cited by this paper
• Overview: hormone refractory prostate cancer

  1999cited by this paper
• Change in serum prostate-specific antigen as a marker of response to cytotoxic therapy for hormone-refractory prostate cancer.

  1998cited by this paper
• Oral estramustine and oral etoposide for hormone-refractory prostate cancer.

  1997cited by this paper
• Comparison of bilateral orchiectomy with or without flutamide for the treatment of patients (PTS) with stage D2 adknocarcinoma of the prostate (CAP): Results of NCI ntergroup study 0105 (SWOG and ECOG)

  1997cited by this paper
• Regulation of androgen receptor (AR) and prostate specific antigen (PSA) expression in the androgen‐responsive human prostate LNCaP cells by ethanolic extracts of the Chinese herbal preparation, PC‐SPES

  1997cited by this paper
• Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer. Adopted on May 17, 1996 by the American Society of Clinical Oncology.

  1996cited by this paper
• Clinical trials in relapsed prostate cancer: defining the target.

  1996influential reference
• How much can we rely on the level of prostate-specific antigen as an end point for evaluation of clinical trials? A word of caution!

  1996cited by this paper
• Suramin-induced decrease in prostate-specific antigen expression with no effect on tumor growth in the LNCaP model of human prostate cancer.

  1996cited by this paper
• Paclitaxel plus estramustine in metastatic hormone-refractory prostate cancer.

  1995cited by this paper
• Evaluation of prostate-specific antigen as a surrogate marker for response of hormone-refractory prostate cancer to suramin therapy.

  1995cited by this paper
• Prospective evaluation of hydrocortisone and suramin in patients with androgen-independent prostate cancer.

  1995cited by this paper
• Estramustine and vinblastine for patients with progressive androgen-independent adenocarcinoma of the prostate.

  1995cited by this paper
• Suramin and hydrocortisone: determining drug efficacy in androgen-independent prostate cancer.

  1995cited by this paper
• Phase II evaluation of oral estramustine and oral etoposide in hormone-refractory adenocarcinoma of the prostate.

  1994cited by this paper
• Surprising activity of flutamide withdrawal, when combined with aminoglutethimide, in treatment of "hormone-refractory" prostate cancer.

  1994cited by this paper
• Current status of monoclonal antibodies for imaging and therapy of prostate cancer.

  1994cited by this paper
• Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer.

  1993cited by this paper
• Vitamin A regulates proliferation and differentiation of human prostatic epithelial cells

  1993cited by this paper
• Selective growth arrest and phenotypic reversion of prostate cancer cells in vitro by nontoxic pharmacological concentrations of phenylacetate.

  1993cited by this paper
• Biomolecular and clinical characteristics of PSA and other candidate prostate tumor markers.

  1993cited by this paper
• Liarozole and 13-cis-retinoic acid anti-prostatic tumor activity.

  1993cited by this paper
• Prostatic cancer: are we closer to rational treatment selection?

  1992cited by this paper
• Phase II study of estramustine and vinblastine, two microtubule inhibitors, in hormone-refractory prostate cancer.

  1992cited by this paper
• Hormonal regulation of prostate‐specific antigen (PSA) glycoprotein in the human prostatic adenocarcinoma cell line, LNCaP

  1992cited by this paper
• The effect of finasteride in men with benign prostatic hyperplasia.

  1992cited by this paper
• Estramustine and vinblastine: use of prostate specific antigen as a clinical trial end point for hormone refractory prostatic cancer.

  1992cited by this paper
• Transcriptional regulation of prostate kallikrein-like genes by androgen.

  1992cited by this paper
• Tumor-promoting phorbol ester down-regulates the androgen induction of prostate-specific antigen in a human prostatic adenocarcinoma cell line.

  1992cited by this paper
• The promoter of the prostate-specific antigen gene contains a functional androgen responsive element.

  1991cited by this paper
• Hormonal regulation of prostate-specific antigen messenger RNA in human prostatic adenocarcinoma cell line LNCaP.

  1991cited by this paper
• Prostate specific antigen in hormonally treated stage D2 prostate cancer: is it always an accurate indicator of disease status?

  1991cited by this paper
• Surrogate endpoints in clinical trials: definition and operational criteria.

  1989cited by this paper
• A kallikrein-like serine protease in prostatic fluid cleaves the predominant seminal vesicle protein.

  1985cited by this paper
• Analysis of survival by tumor response.

  1983cited by this paper
• Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples.

  1977cited by this paper
• Regression models and life tables (with discussion

  1972cited by this paper
• Nonparametric Estimation from Incomplete Observations

  1958cited by this paper
• HORMONAL REGULATION

  1938cited by this paper

• Evaluation of exposure‐response‐safety relationship of model‐informed low‐dose 500 mg abiraterone acetate in prostate cancer patients

  2025cites this paper
• Cytoreductive radical prostatectomy: who benefits from the surgical approach?

  2023cites this paper
• An analysis of survival in patients with castrate-resistant prostate cancer receiving enzalutamide with treatment breaks

  2021cites this paper
• Using medical claims database to develop a population disease progression model for leuprorelin-treated subjects with hormone-sensitive prostate cancer

  2020cites this paper
• Correlation of Prostate-specific Antigen Kinetics with Overall Survival and Radiological Progression-free Survival in Metastatic Castration-sensitive Prostate Cancer Treated with Abiraterone Acetate plus Prednisone or Placebos Added to Androgen Deprivation Therapy: Post Hoc Analysis of Phase 3 LATIT

  2019cites this paper
• Traditional Medicinal Plants and Their Therapeutic Potential Against Major Cancer Types

  2018cites this paper
• Favourable response of serum prostate-specific antigen to conjugated oestrogen in castrate-resistant prostate cancer in Jamaica

  2018cites this paper
• Prostate-Specific Antigen as a Marker of Disease Activity in Prostate Cancer : Part 2 Review

  2017cites this paper
• Prostate-Specific Antigen as a Marker of Disease Activity in Prostate Cancer : Part 2

  2017influential citation
• Actual role and perspectives in the treatment of hormone refractory prostatic cancer

  2017cites this paper
• Predictive Models in Castration Resistant Prostate Cancer

  2016cites this paper
• Very Early PSA Response to Abiraterone in mCRPC Patients: A Novel Prognostic Factor Predicting Overall Survival

  2016cites this paper
• Cabazitaxel for the Treatment of Prostate Cancer

  2016cites this paper
• Prognostic value of pretreatment serum lactate dehydrogenase level in patients with solid tumors: a systematic review and meta-analysis

  2015cites this paper
• Prognostic, predictive and potential surrogate markers in castration-resistant prostate cancer

  2015cites this paper
• MicroRNA expression signature of castration-resistant prostate cancer: the microRNA-221/222 cluster functions as a tumour suppressor and disease progression marker

  2015cites this paper
• [Management of non metastatic castration resistant prostate cancer].

  2015cites this paper
• Efficacy of treatment with a GnRH antagonist in prostate cancer patients previously treated with a GnRH agonist

  2015cites this paper
• False-positive diagnosis of disease progression by magnetic resonance imaging for response assessment in prostate cancer with bone metastases: A case report and review of the pitfalls of images in the literature.

  2015cites this paper
• Prostate-specific antigen kinetic profiles during androgen deprivation therapy as prognostic factors in castration-resistant prostate cancer.

  2015influential citation
• Defining Clinical Endpoints in Castration-Resistant Prostate Cancer

  2014cites this paper
• A critical review of the analytical approaches for circulating tumor biomarker kinetics during treatment.

  2014cites this paper
• Metastatic castration resistant prostate cancer: current strategies of management in the Middle East.

  2014cites this paper
• Whole-Body 18F-Fluorocholine (FCH) PET/CT and MRI of the Spine for Monitoring Patients With Castration-Resistant Prostate Cancer Metastatic to Bone: A Pilot Study

  2014cites this paper
• The microRNA-23b/27b/24-1 cluster is a disease progression marker and tumor suppressor in prostate cancer

  2014cites this paper
• Androgen dynamics and serum PSA in patients treated with abiraterone acetate

  2014cites this paper
• Radiation Safety Considerations for the Use of 223RaCl2 DE in Men with Castration-resistant Prostate Cancer

  2014cites this paper
• PSA response rate as a surrogate marker for median overall survival in docetaxel-based first-line treatments for patients with metastatic castration-resistant prostate cancer: an analysis of 22 trials

  2014cites this paper
• A phase II trial of personalized peptide vaccination in castration-resistant prostate cancer patients: prolongation of prostate-specific antigen doubling time

  2013cites this paper
• Prostate-specific antigen changes as surrogate for overall survival in men with metastatic castration-resistant prostate cancer treated with second-line chemotherapy.

  2013cites this paper
• A switch from GnRH agonist to GnRH antagonist in castration-resistant prostate cancer patients leads to a low response rate on PSA

  2013cites this paper
• Biomarkers in the management and treatment of men with metastatic castration-resistant prostate cancer.

  2012cites this paper
• Cabazitaxel for Metastatic Castrate-Resistant Prostate Cancer: A Case Presentation

  2012cites this paper
• Cost Effectiveness of Risk-Prediction Tools in SelectingPatients for Immediate Post-Prostatectomy Treatment

  2012cites this paper
• Clinical development of novel therapeutics for castration‐resistant prostate cancer

  2012cites this paper
• Changes of transthyretin and clusterin after androgen ablation therapy and correlation with prostate cancer malignancy.

  2012cites this paper
• Significant associations of prostate cancer susceptibility variants with survival in patients treated with androgen‐deprivation therapy

  2012cites this paper
• Phase II trial of simple oral therapy with capecitabine and cyclophosphamide in patients with metastatic breast cancer: SWOG S0430.

  2012cites this paper
• Obesity and prostate cancer: epidemiology, genetics and molecular and cellular mechanisms

  2012cites this paper
• Significant associations of prostate-specific antigen nadir and time to prostate-specific antigen nadir with survival in prostate cancer patients treated with androgen-deprivation therapy

  2012cites this paper
• End points and outcomes in castration-resistant prostate cancer: from clinical trials to clinical practice.

  2011cites this paper
• An update on TroVax® for the treatment of progressive castration-resistant prostate cancer

  2011cites this paper
• Impact of prostate‐specific antigen (PSA) nadir and time to PSA nadir on disease progression in prostate cancer treated with androgen‐deprivation therapy

  2011cites this paper
• Biomarqueurs émergents dans le cancer de prostate : à propos de la β-tubuline de classe III et du score urinaire PCA3

  2011cites this paper
• Immunotherapy in prostate cancer: emerging strategies against a formidable foe.

  2011cites this paper
• Lactate dehydrogenase, Gleason score and HER-2 overexpression are significant prognostic factors for M1b prostate cancer.

  2011cites this paper
• Challenges for the Development of New Agents in Prostate Cancer

  2010cites this paper
• Investigation of risk factors for prostate cancer patients with bone metastasis based on clinical data.

  2010cites this paper
• Salvage chemotherapy for hormone-refractory prostate cancer: Association of Adriamycin and ifosfamide.

  2010cites this paper
• Lycopene for advanced hormone refractory prostate cancer: a prospective, open phase II pilot study.

  2009cites this paper
• Dendritic-cell vaccination for prostate cancer.

  2009cites this paper
• Clinical Progression to Castration-Recurrent Prostate Cancer

  2009cites this paper
• Therapeutic Vaccination with an Interleukin-2–Interferon-γ-Secreting Allogeneic Tumor Vaccine in Patients with Progressive Castration-Resistant Prostate Cancer: A Phase I/II Trial

  2009cites this paper
• Cost effectiveness of risk-prediction tools in selecting patients for immediate post-prostatectomy treatment.

  2009cites this paper
• Treatment of Hormone-Refractory Prostate Cancer with Docetaxel or Mitoxantrone: Relationships between Prostate-Specific Antigen, Pain, and Quality of Life Response and Survival in the TAX-327 Study

  2008cites this paper
• Sipuleucel-T: A Vaccine for Metastatic, Asymptomatic, Androgen-Independent Prostate Cancer

  2008cites this paper
• New Perspectives on Chemotherapy in Prostate Cancer

  2008cites this paper
• Multizentrische Therapieoptimierungsstudie zum Einsatz von Docetaxel (Taxotere®) und Mitoxantron (Novantron®) in der Therapie des hormonrefraktären Prostatakarzinoms

  2008cites this paper
• A Pilot Trial of CTLA-4 Blockade with Human Anti-CTLA-4 in Patients with Hormone-Refractory Prostate Cancer

  2007cites this paper
• Positron emission tomography imaging as a cancer biomarker

  2007cites this paper
• Is proton beam therapy cost effective in the treatment of adenocarcinoma of the prostate?

  2007cites this paper
• Hormone-refractory prostate cancer: choosing the appropriate treatment option.

  2007cites this paper
• Current indications for chemotherapy in prostate cancer patients.

  2007cites this paper
• Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer.

  2007cites this paper
• [Active immunotherapy of prostate cancer with a focus on dendritic cells].

  2007cites this paper
• Immunotherapy with dendritic cells for prostate cancer

  2007cites this paper
• [Prognostic factors of localised, locally advanced or metastatic prostate cancer].

  2007cites this paper
• Patients with Hormone-Refractory Prostate Cancer A Pilot Trial of CTLA-4 Blockade with Human Anti-CTLA-4 in Updated

  2007cites this paper
• Inmunoterapia activa en cáncer de próstata: Revisión con atención especial a las células dendríticas

  2007cites this paper
• Markers of bone metabolism in prostate cancer.

  2006cites this paper
• Prostate‐specific antigen velocity and survival for patients with hormone‐refractory metastatic prostate carcinoma

  2006influential citation
• Molecular Imaging, Clinical Trial Design, and the Development of Emerging Therapies for Metastatic Prostate Cancer

  2006cites this paper
• Post-therapy changes in PSA as an outcome measure in prostate cancer clinical trials

  2006cites this paper
• Using decision analysis to determine the cost-effectiveness of intensity-modulated radiation therapy in the treatment of intermediate risk prostate cancer.

  2006cites this paper
• Evaluating Chemical Structure Similarity as an Indicator of Cellular Growth Inhibition

  2006cites this paper
• Re: Secondary Hormonal Therapy for Advanced Prostate Cancer

  2006cites this paper
• Changing perspectives of the role of chemotherapy in advanced prostate cancer.

  2006cites this paper
• Secondary hormonal therapy for advanced prostate cancer.

  2006cites this paper
• Vaccination with BLP25 liposome vaccine to treat non-small cell lung and prostate cancers

  2005cites this paper
• Fluorodeoxyglucose Positron Emission Tomography as an Outcome Measure for Castrate Metastatic Prostate Cancer Treated with Antimicrotubule Chemotherapy

  2005cites this paper
• Prostate-specific antigen response duration and risk of death for patients with hormone-refractory metastatic prostate cancer.

  2005cites this paper
• Chemotherapy for advanced prostate cancer: Results of new clinical trials and future studies

  2005cites this paper
• Present Status and Perspectives in the Treatment of Hormone-Refractory Prostate Cancer

  2005cites this paper
• Advances in Prostate Cancer Chemotherapy: A New Era Begins 1

  2005cites this paper
• Effect of docetaxel in patients with hormone-dependent prostate-specific antigen progression after local therapy for prostate cancer.

  2005cites this paper
• Is prostate-specific antigen a valid surrogate end point for survival in hormonally treated patients with metastatic prostate cancer? Joint research of the European Organisation for Research and Treatment of Cancer, the Limburgs Universitair Centrum, and AstraZeneca Pharmaceuticals.

  2005cites this paper
• Long-term outcome for men with androgen independent prostate cancer treated with ketoconazole and hydrocortisone.

  2005cites this paper
• Cost–effectiveness of intensity-modulated radiation therapy

  2005cites this paper
• Erkenntnisse und Ergebnisse einer prospektiven klinischen Phase II Studie zur Chemotherapie des hormonrefraktären Prostatakarzinoms mit PEG-liposomalen Doxorubicin (Caelyx R )

  2005cites this paper
• Phase I Clinical and Pharmacokinetic Study of Kahalalide F in Patients with Advanced Androgen Refractory Prostate Cancer

  2005cites this paper
• Prostate Cancer Clinical Trial End Points: “RECIST”ing a Step Backwards

  2005cites this paper
• Clinical trials in metastatic prostate cancer--has there been real progress in the past decade?

  2005cites this paper
• [Diagnosis and management of advanced hormone-refractory prostate cancer: results of a practice survey on 301 French urologists].

  2004cites this paper
• Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583).

  2004cites this paper
• Update on hormone-refractory prostate cancer

  2004cites this paper
• The selection of hormonal therapy in prostate cancer: who, when, and for how long?

  2004cites this paper
• The future in advanced prostate cancer: take your partners or is the last dance for me?

  2004cites this paper
• The natural history of androgen independent prostate cancer.

  2004cites this paper
• A Weekly Schedule of Docetaxel for Metastatic Hormone-Refractory Prostate Cancer

  2004cites this paper
• Effect of combination therapy with aminoglutethimide and hydrocortisone on prostate-specific antigen response in metastatic prostate cancer refractory to standard endocrine therapy

  2004cites this paper